205 related articles for article (PubMed ID: 12966906)
1. Monoclonal antibodies in the treatment of cancer, Part 2.
Cersosimo RJ
Am J Health Syst Pharm; 2003 Aug; 60(16):1631-41; quiz 1642-3. PubMed ID: 12966906
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies in the treatment of cancer, Part 1.
Cersosimo RJ
Am J Health Syst Pharm; 2003 Aug; 60(15):1531-48. PubMed ID: 12951753
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects.
Leone G; Sica S; Voso MT; Rutella S; Pagano L
Cardiovasc Hematol Agents Med Chem; 2006 Jan; 4(1):33-52. PubMed ID: 16529548
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody therapy of leukaemias and lymphomas.
Jacobs SA; Foon KA
Expert Opin Biol Ther; 2005 Sep; 5(9):1225-43. PubMed ID: 16120052
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapy.
Moccia A; Ghielmini M
Semin Hematol; 2008 Apr; 45(2):75-84. PubMed ID: 18381101
[TBL] [Abstract][Full Text] [Related]
7. ["Magic bullets"--monoclonal antibodies in acute leukemia and non-Hodgkin's lymphoma treatment].
Łuczyński W; Krawczuk-Rybak M
Postepy Hig Med Dosw; 2002; 56(6):789-801. PubMed ID: 12669700
[TBL] [Abstract][Full Text] [Related]
8. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody therapy in lymphoid malignancies.
Hainsworth JD
Oncologist; 2000; 5(5):376-84. PubMed ID: 11040273
[TBL] [Abstract][Full Text] [Related]
10. [Monoclonal antibodies in hematology in 2009].
Bonnet C; Beguin Y; De Prijck B; Witvrouw N; Hustinx R; Fillet G
Rev Med Liege; 2009; 64(5-6):268-73. PubMed ID: 19642457
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
Rao AV; Schmader K
Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
[TBL] [Abstract][Full Text] [Related]
12. Infectious complications associated with immunomodulating monoclonal antibodies used in the treatment of hematologic malignancy.
Koo S; Baden LR
J Natl Compr Canc Netw; 2008 Feb; 6(2):202-13. PubMed ID: 18319052
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody therapy for lymphoma.
Campbell P; Marcus R
Blood Rev; 2003 Sep; 17(3):143-52. PubMed ID: 12818224
[TBL] [Abstract][Full Text] [Related]
14. Overview of monoclonal antibodies in cancer therapy: present and promise.
Stern M; Herrmann R
Crit Rev Oncol Hematol; 2005 Apr; 54(1):11-29. PubMed ID: 15780905
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
16. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients.
Grillo-López AJ
Expert Rev Anticancer Ther; 2002 Jun; 2(3):323-9. PubMed ID: 12113055
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies in the treatment of chronic lymphocytic leukemia.
Liu NS; O'Brien S
Med Oncol; 2004; 21(4):297-304. PubMed ID: 15579912
[TBL] [Abstract][Full Text] [Related]
18. [Monoclonal antibody treatment of malignant lymphoma].
Buske C; Dreyling M; Unterhalt M; Hiddemann W
Internist (Berl); 2004 Dec; 45(12):1370-7. PubMed ID: 15517123
[TBL] [Abstract][Full Text] [Related]
19. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
20. Antibody therapy in non-Hodgkin's lymphoma: the role of rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab.
Fietz T; Thiel E
Recent Results Cancer Res; 2007; 176():153-63. PubMed ID: 17607923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
